Start-Up Previews, December 2014
Executive Summary
This Month's Profile Group: Closing In On An Artificial Pancreas, features profiles of Beta-O2, Defymed, and Pancreum. Plus these Start-Ups Across Health Care: Biogelx, COTA, Kesios Therapeutics, and OtoKinetics.
You may also be interested in...
OtoKinetics Inc.
Currently, people with severe hearing loss are treated with conventional hearing aids, which have less than a 50% success rate due to such problems as feedback and discomfort. OtoKinetics Inc. hopes to increase that efficacy rate to at least 90% with its Krescendo implant, a titanium device about the size of a grain of rice that is inserted into the cochlea.
Closing In On An Artificial Pancreas
Medtronic may be the front-runner in the race to market, but a number of medtech start-ups hope investors will find merit in their innovative technologies. Profiles of Beta-O2, Defymed, and Pancreum.
Defymed Inc.
Defymed Inc.’s MAILPAN (MAcro-encapsulation of PANcreatic Islets) is a bioartificial pancreas that can use a broader pool of cell types while protecting the cells from rejection by the immune system.